



Initial data from Neogap Therapeutics' personalised immunotherapy trial supports a positive safety profile

Neogap Therapeutics AB, a Swedish biotechnology company developing personalised immunotherapy for cancer treatment, announces that initial safety data from the first patients in its ongoing phase I/II trial corroborates that the treatment is well tolerated. No serious treatment-related adverse events have been observed, reinforcing confidence in the therapy's safety profile.



“Safety data from the first two treated patients confirm that Neogap’s immunotherapy is well tolerated and further strengthen our confidence in its potential as a valuable treatment option for patients with difficult-to-treat cancer. The trial is progressing as planned, and we continue to gather data to assess the safety profile and analyse clinical outcomes and biomarkers as part of the exploratory evaluation,” says Samuel Svensson, CEO of Neogap Therapeutics.

The ongoing phase I/II trial is a first-in-human study designed to assess the safety and tolerability of Neogap’s personalised immunotherapy, pTTL (personalised Tumour Trained Lymphocytes), in patients with advanced colorectal cancer. Several patients have already been enrolled, with the first having completed treatment. Recruitment and treatment of additional patients continue. In total, 12–16 patients are planned to receive treatment. The study is being conducted at several hospitals in Sweden, including Karolinska University Hospital, Västmanland Hospital, and Danderyd Hospital.

About Neogap's immunotherapy, pTTL

pTTL is a cell-based immunotherapy designed to enhance the patient's own T cells to fight cancer. The therapy combines advanced DNA sequencing with T-cell expansion, enabling

precision treatment for solid tumours. It is powered by Neogap's patented technologies, PIOR® and EpiTCer®. The goal is to provide patients with a tailored and innovative therapy that meets their specific needs.

European
Innovation
Council



Co-funded by
the European Union

Project reference number: 190185439 – NEOpTTL

Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or EISMEA. Neither the European Union nor the granting authority can be held responsible for them.

For more information, please contact:

Samuel Svensson, CEO

Email: samuel.svensson@neogap.se

Phone: +46 733 54 21 94

About Neogap Therapeutics

Neogap Therapeutics is a Swedish clinical-stage biotechnology company focused on developing personalised cancer immunotherapy using the patient's own cells. The therapy is based on the company's two technologies PIOR® and EpiTCer®. PIOR® is sophisticated software that uses DNA sequencing data from the patient and machine learning algorithms to select tumour-specific mutations. Then, EpiTCer® is used to multiply T cells that can recognize and attack the selected tumor-specific targets. Neogap is located at Cancer Center Karolinska in Stockholm. To learn more about Neogap and its cutting-edge research, please visit neogap.se and follow Neogap on [LinkedIn](#).